Lymphatix, a spin-off company from Helsinki University and Ludwig Cancer Institute has been sold to London based public company Ark Therapeutics. Lymphatix has developed new gene-based drugs to treat human conditions with impaired blood supply (e.g. heart ischemia) or lymphoid drainage (e.g. edema).

See press release by Ark:

http://investors.arktherapeutics.com/servlet/HsPublic?contex t=ir.access&ir_option=RNS_NEWS&item=57266946911110&ir_ client_id=4553&transform=newsitem_new

"Lympahatix is a prime example of Licentia's effort to commercialize academic discoveries through establishment of new start-up companies that will generate value prior selling them to third parties", comments Licentia's acting CEO Markku Jalkanen. "The Lymphatix drug development programs are now taken further by Ark's world leading experts in gene therapy", finishes Jalkanen.